Blood Pressure and Stroke: An Overview of Published Reviews

Stroke

Volumn 35, Issue 3, 2004, Pages 776-785

  Lawes, Carlene M M ^a   Bennett, Derrick A ^a   Feigin, Valery L ^a   Rodgers, Anthony ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Blood pressure; Cohort studies; Epidemiology; Meta analysis; Randomized controlled trials; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PERINDOPRIL; PLACEBO;

AGE; ANTIHYPERTENSIVE THERAPY; ASIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; EMBASE; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; MORTALITY; NORTH AMERICA; PACIFIC ISLANDS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SEX DIFFERENCE; STROKE; SYSTOLIC BLOOD PRESSURE; WESTERN EUROPE;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ASIA; BLOOD PRESSURE; CAUSALITY; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NORTH AMERICA; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK; TREATMENT OUTCOME;

EID: 1442274760     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000116869.64771.5A     Document Type: Review

References (93)

1. World Health Organisation. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organisation; 2002.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J, et al. Blood pressure, stroke, and coronary heart disease, part I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
3. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
4. MacMahon S, Rodgers A. The effects of anti-hypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vasc Med Biol. 1993;4:265-271.
5. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens. 1993;15:967-978.
6. Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers TC. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med. 1994;121:355-362.
7. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry M, et al, for the INDANA Investigators. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med. 1997;126:761-767.
8. He J, Whelton PK. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens Suppl. 1999;17:S7-S13.
9. Gueyffier F, Boutitie F, Boissel JP, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry HM, Pocock S. INDANA: a meta-analysis on individual patient data in hypertension: protocol and preliminary results. Therapie. 1995;50:353-362.
10. Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens. 1996;10:1-8.
11. Neal B, MacMahon S, Chapman N, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-1964.
12. Hedges LV, Olkin I. Statistical Methods for Meta-analysis. London, UK: Academic Press; 1985.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
14. Light RJ, Pillemer DB. Summing Up: The Science of Reviewing Research. Cambridge, Mass: Harvard University Press; 1984.
15. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 45,000 people in 45 prospective cohorts. Lancet. 1995;346:1647-1653.
16. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
17. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet. 1998;352:1801-1807.
18. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21:707-716.
19. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001;38:E28-E32.
20. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101-105.
21. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
22. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
23. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
24. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720.
25. Feigin VL, Lawes CMM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2:43-53.
26. Truelsen T, Bonita R, Jamrozik K. Surveillance of stroke: a global perspective. Int J Epidemiol. 2001;30(suppl 1):S11-S16.
27. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
28. Gueyffier F, Bulpitt C, Boissel J-P, Schron E, Ekbom T, Fagard R, Casiglia E, Kerlikowske K, Coope J, for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet. 1999;353:793-796.
29. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324:699-702.
30. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
31. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
32. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
33. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet. 1979;1:861-865.
34. Kannel WB, D'Agostino RB, Silbershatz H. Blood pressure and cardiovascular morbidity and mortality rates in the elderly. Am Heart J. 1997;134:758-763.
35. Cruickshank JM. J curve in antihypertensive therapy: does it exist? A personal point of view. Cardiovasc Drugs Ther. 1994;8:757-760.
36. D'Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ. 1991;303:385-389.
37. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489-495.
38. Alderman MH. Blood pressure J-curve: is it cause or effect? Curr Opin Nephrol Hypertens. 1996;5:209-213.
39. MacMahon S, Rodgers A, Neal B, Chalmers J. Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. Hypertension. 1997;29:537-538.
40. Sleight P. Lowering of blood pressure and artery stiffness. Lancet. 1997;349:362.
41. Sleight P. Lowering of blood pressure and artery stiffness. Lancet. 1997;349:955-956.
42. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316, 099 white men. Arch Intern Med. 1992;152:56-64.
43. Flack JM, Neaton J, Grimm R Jr, Shih J, Cutler J, Ensrud K, MacMahon S, for the Multiple Risk Factor Intervention Trial Research Group. Blood pressure and mortality among men with prior myocardial infarction. Circulation. 1995;92:2437-2445.
44. McMurray J, McInnes GT. The J-curve hypothesis. Lancet. 1992;339:561-562.
45. Pfeffer MA. Angiotensin-converting enzyme inhibition in congestive heart failure: benefit and perspective. Am Heart J. 1993;126(pt 2):789-793.
46. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
47. Staessen J, Fagard R, Thijs L, Celis H, Arabidze G, Birkenhager W, Bulpitt C, Leeuw PD, Dollery C, Fletcher AE, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
48. PROGRESS Collaborative Group. The lowering of blood-pressure after stroke. Lancet. 2001;358:1994-1995.
49. Murray CJL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard University Press; 1996.
50. Report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet. 1980;1:1261-1267.
51. Control of moderately raised blood pressure: report of a co-operative randomized controlled trial. BMJ. 1973;3:434-436.
52. Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970;1:485-489.
53. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ. 1986;293:1145-1151.
54. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke. 1993;24:543-548.
55. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, Forette F. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349-1354.
56. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program, I: reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562-2571.
57. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program, II: mortality by race-sex and age. JAMA. 1979;242:2572-2577.
58. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program, III: reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:633-638.
59. The effect of treatment on mortality in "mild" hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med. 1982;307:976-980.
60. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris: 5-year findings of the Hypertension Detection and Follow-up Program. Hypertension. 1984;6(pt 2):I198-I206.
61. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA. 1974;229:409-418.
62. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
63. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97-104.
64. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial: the Oslo study. Am J Med. 1980;69:725-732.
65. Leren P, Helgeland A. Oslo Hypertension Study. Drugs. 1986;31(suppl 1):41-45.
66. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
67. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
68. Smith WM. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res. 1977;40(suppl 1):I98-I105.
69. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034.
70. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-1152.
71. Perry HM Jr. Treatment of mild hypertension: preliminary results of a two-year feasibility trial. Circ Res. 1977;40(suppl 1):I180-I187.
72. Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial: plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Ann N Y Acad Sci. 1978;304:267-292.
73. Wolff FW, Lindeman RD. Effects of treatment in hypertension: results of a controlled study. J Chron Dis. 1966;19:227-240.
74. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
75. MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T, Hart H, Scott J, White H, for the PART-2 Collaborative Research Group. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease: Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol. 2000;36:438-443.
76. Cashin-Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees RS, for the QUIET Investigators. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet: QUinapril Ischemic Event Trial. Am J Cardiol. 1999;83:43-47.
77. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000;102:1748-1754.
78. Eriksson S, Olofsson BO, Wester PO. Atenolol in secondary prevention after stroke. Cerebrovasc Dis. 1995;5:21-25.
79. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
80. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
81. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, et al. Second Australian National Blood Pressure Study: a comparison of outcomes with angiotensin-converting- enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
82. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
83. Casiglia E, Spolaore P, Mazza A, Ginocchio G, Colangeli G, Onesto C, Di Menza G, Pegoraro L, Ambrosio GB. Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL). Jpn Heart J. 1994;35:589-600.
84. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
85. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422-2427.
86. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.
87. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, Kappagoda T, Rocco MV, Schnaper HW, Sowers JR, Bond MG. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA. 1996;276:785-791.
88. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension. 1999;34:1129-1133.
89. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-365.
90. Zanchetti A, Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens. 1998;16:1667-1676.
91. Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A, Zanchetti A, for the VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens. 1997;15:1337-1344.
92. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
93. Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med. 1991;10:1025-1035.